IL2 and neoplasm: Consistent with previous studies [33], concomitant analyses of immune activation cytokines indicated that nivolumab treatment also significantly increased the production of IFN-γ, IL-2, and TNF-α (Figure 1B and Supplementary Table S1), of which IFN-γ has been a key cytokine in IL-10 mediated anti-tumor responses [16].